Report finanziari

Home

27 Novembre 2024

Neopharmed Gentili S.p.A. – Risultati Finanziari del Q3 2024 YTD

DOWNLOAD INTERIM REPORT

DOWNLOAD PRESENTATION RESULTS

28 Agosto 2024

Neopharmed Gentili S.p.A. – Risultati Finanziari del H1 2024

DOWNLOAD INTERIM REPORT

DOWNLOAD PRESENTATION RESULTS

24 Giugno 2024

Neopharmed Gentili S.p.A. – Risultati Finanziari del Q1 2024

DOWNLOAD INTERIM REPORT

DOWNLOAD PRESENTATION RESULTS

Neopharmed Gentili S.p.A. | Via S.G.Cottolengo, 15 20143 Milano | C.F. e P.I 06647900965
Iscrizione registro imprese di Milano n. 1905235 | Capitale sociale € 1.161.212,00

Disclaimer

This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

The securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”); (ii) a customer within the meaning of Directive 2016/97/EU (as amended), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a “qualified investor” as defined in Regulation (EU) 2017/1129 (as amended). Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering, selling or distributing the securities or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the securities or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPS Regulation.

In member states of the EEA, this announcement and any offer of the securities referred to herein in any Member State of the European Economic Area (“EEA”) will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of the securities referred to herein. Accordingly, any person making or intending to make an offer in a Member State of Notes which are the subject of the offering contemplated may only do so in circumstances in which no obligation arises for the Issuers or any of the initial purchasers to publish a prospectus pursuant to Article 3 of the Prospectus Regulation, in each case, in relation to such offer. Neither the Issuer nor the initial purchasers have authorized, nor do they authorize, the making of any offer of Notes in circumstances in which an obligation arises for the Issuers or the initial purchasers to publish a prospectus for such offer. The expression “Prospectus Regulation” means Regulation (EU) 2017/1129.

The securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom (“UK”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (“EUWA”); (ii) a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a “qualified investor” as defined in Article 2 of the Prospectus Regulation as it forms part of UK domestic law by virtue of the EUWA (the “UK Prospectus Regulation”). Consequently no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the “UK PRIIPs Regulation”) for offering or selling the Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.

In the UK, this announcement and any offer of the securities referred to herein in the UK will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of the securities referred to herein. Accordingly, any person making or intending to make an offer in the UK of Notes which are the subject of the offering contemplated may only do so in circumstances in which no obligation arises for the Issuers or any of the initial purchasers to publish a prospectus pursuant to Article 3 of the UK Prospectus Regulation, in each case, in relation to such offer. Neither the Issuer nor the initial purchasers have authorized, nor do they authorize, the making of any offer of Notes in circumstances in which an obligation arises for the Issuers or the initial purchasers to publish a prospectus for such offer. The expression “UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA.

This communication is being distributed only to, and is directed at persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”) (ii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Promotion Order, (iii) are outside the United Kingdom or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 in connection with the issue and sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

The securities will not be listed on an Italian regulated market, therefore no documents or materials relating to the securities have been or will be submitted to the clearance procedure of the competent authority.

Each subsequent page should bear the legend:

Not for release, publication or distribution, directly or indirectly, in the United States, the United Kingdom, Canada, Australia or Japan or in any other jurisdiction in which offers or sales would be prohibited by applicable law.

Disclaimer

AVVISO IMPORTANTE: è necessario leggere le seguenti informazioni prima di continuare.
L'accesso alle informazioni e ai documenti nella parte del nostro sito Web che segue questo disclaimer (la "Sezione IR") è limitato per motivi normativi. Accedendo alla Sezione IR si riterrà che tu abbia letto e accettato i termini del presente disclaimer. Le informazioni contenute nella Sezione IR e nelle relazioni, bilanci, comunicati stampa, presentazioni e altri documenti disponibili nella Sezione IR (le “Informazioni”) non costituiscono un'offerta di vendita o una sollecitazione di un'offerta per l'acquisto di titoli di Neopharmed S.p.A. (la “Società”) o di qualsiasi delle sue controllate o affiliate. È necessario rispettare tutte le leggi applicabili in qualsiasi luogo in cui acquisti, offri o vendi titoli o accedi o possiedi le Informazioni.
Tutti i titoli a cui si fa riferimento nelle Informazioni non sono stati e non saranno registrati ai sensi del Securities Act degli Stati Uniti del 1933, come modificato (il "Securities Act") e possono essere offerti o venduti solo a investitori che siano (i) acquirenti istituzionali qualificati (ai sensi della Rule 144A del Securities Act) negli Stati Uniti o (ii) al di fuori degli Stati Uniti in transazioni offshore in conformità con il Regolamento S del Securities Act (e, se gli investitori sono residenti in uno Stato membro dello Spazio Economico Europeo, un investitore qualificato ai sensi dell'articolo 2, lettera e), del regolamento (UE) 2017/1129, come modificato, e qualsiasi misura di attuazione pertinente in ciascuno Stato membro dello Spazio economico europeo).
Riconosci che le informazioni e le dichiarazioni contenute nel documento a cui stai accedendo su questo sito web si riferiscono esclusivamente alla data di tale documento (o a eventuali altre date specificate al suo interno) e tali informazioni e dichiarazioni potrebbero diventare inaccurate, obsolete e/o superate in seguito e non dovrebbero essere considerate attendibili per qualsiasi decisione di investimento.Riconosci che i materiali su questo sito web ai quali stai accedendo sono riservati e destinati esclusivamente a te e accetti di non inoltrare, riprodurre, copiare, scaricare o pubblicare nessuno di tali materiali (elettronicamente o in altro modo) a nessun'altra persona se ciò non è conforme alla legge.
Riconosci che l'accesso alle informazioni e ai documenti contenuti in questa parte del sito web potrebbe essere illegale in alcune giurisdizioni e solo determinate categorie di persone potrebbero essere autorizzate ad accedere a questa parte del sito web. Se non sei autorizzato ad accedere alle informazioni e ai documenti contenuti in questa parte del sito web o non sei sicuro di poter visualizzare tali materiali, dovresti lasciare questa parte del sito web.
Riconosci che non è stata ottenuta alcuna registrazione o approvazione e che la Società e le sue affiliate non assumono alcuna responsabilità in caso di violazione di leggi e regolamenti applicabili da parte di chiunque.
Cliccando il pulsante qui sotto contrassegnato come "Sì", confermi di aver letto e compreso l'avviso legale sopra riportato.
Se non puoi confermare, devi cliccare sul pulsante contrassegnato come "No" o uscire in altro modo da questa parte del sito web.

Report finanziari

27 Novembre 2024

Neopharmed Gentili S.p.A. – Risultati Finanziari del Q3 2024 YTD

28 Agosto 2024

Neopharmed Gentili S.p.A. – Risultati Finanziari del H1 2024

20 Marzo 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent eget arcu iaculis nisi commodo ultricies.

24 Giugno 2024

Neopharmed Gentili S.p.A. – Risultati Finanziari del Q1 2024

20 Marzo 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent eget arcu iaculis nisi commodo ultricies.